Phase II Study of Single-Agent Orteronel (TAK-700) in Patients with Nonmetastatic Castration-Resistant Prostate Cancer and Rising Prostate-Specific Antigen
Year: 2014
Type: article
Study design: Clinical Trial
Source: Clinical Cancer Research
Institutions: University of Michigan, U-M Rogel Cancer Center, The University of Texas MD Anderson Cancer Center, Harvard University, Massachusetts General Hospital, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Oregon Health & Science University, OHSU Knight Cancer Institute, University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center, University of Wisconsin–Madison, University of Wisconsin Carbone Cancer Center, Takeda Oncology (United States), Duke University, Duke Medical Center
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2145674845